EP0995751A2 — Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
Assigned to Pfizer Ltd Great Britain · Expires 2000-04-26 · 26y expired
What this patent protects
There is provided compounds of formula IA and of formula IB, wherein R 1 , R 2 , R 3 , R 4 and A have meanings given in the description, which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3',5'-monophos…
USPTO Abstract
There is provided compounds of formula IA and of formula IB, wherein R 1 , R 2 , R 3 , R 4 and A have meanings given in the description, which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3',5'-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
Drugs covered by this patent
- Pemazyre (PEMIGATINIB) · Incyte Corp
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.